New single-use momentum, Sartoflow Advance targets flexible mid-scale TFF

Sartorius Stedim’s Sartoflow Advance system extends the company’s single-use tangential flow filtration lineup with a modular skid for flexible mid-scale biologics manufacturing, aimed at monoclonal antibodies, recombinant proteins and vaccines in hybrid or fully disposable plants.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 10:15 PM ET. Details in the imprint.

Sartorius Stedim Biotech is expanding its downstream processing portfolio with the Sartoflow Advance, a newly introduced tangential flow filtration system designed for flexible, mid-scale biologics and vaccine manufacturing. The skid is positioned as a modular, configurable platform that supports both single-use and reusable flow paths to help process engineers design hybrid or fully disposable purification lines for modern biologics plants. According to Sartorius, the system targets concentration and diafiltration steps for monoclonal antibodies, recombinant proteins and similar large-molecule therapeutics at working volumes from a few liters up to roughly 200 liters, depending on cassette configuration and process design. The launch underscores how the company is sharpening its single-use offering as drug developers push for faster changeovers and more scalable, standardized filtration hardware across development and clinical manufacturing.

How Sartoflow Advance fits into single-use tangential flow filtration

Sartoflow Advance sits in the heart of Sartorius Stedim’s tangential flow filtration lineup as a mid-scale, configurable skid meant to bridge process development and clinical or small commercial batches while using the same core filtration technologies. Sartorius describes the unit as a modular system optimized for ultrafiltration and diafiltration of monoclonal antibodies, recombinant proteins and vaccine candidates, with a focus on rapid product changeovers, recipe-based automation and integration into broader single-use downstream trains. The platform supports single-use flow kits as well as stainless-steel and reusable components so that manufacturers can combine disposable elements for fast turnaround with traditional hardware where long-term durability or specific cleaning regimes are required, allowing a tailored balance of capital expenditure and operating cost in each facility. A key design goal is to enable process standardization across multiple sites and products by using consistent software, sensor suites and cassette interfaces, which is increasingly important for global contract development and manufacturing organizations running diverse client pipelines.

From an engineering perspective, Sartoflow Advance is built as a skid-based TFF platform that can be configured with different pump sizes, filter cassette areas and automation levels to match a wide range of process titers and target batch volumes. Sartorius highlights that typical working volumes span from small development batches of a few liters up to around 200 liters, covering much of the clinical-scale ultrafiltration and diafiltration space where manufacturers require scalability without committing to very large, fixed stainless-steel systems. The company has emphasized in product materials that the skid is optimized for both ultrafiltration, where the goal is to concentrate a biomolecule such as a monoclonal antibody, and diafiltration, where buffer exchange is needed ahead of final formulation or storage, placing Sartoflow Advance squarely in critical polishing and formulation-prep steps. By aligning its design with established Sartorius cassettes and control strategies, the system can slot into existing Sartorius process architectures with relatively limited revalidation work, an important factor for regulated biopharmaceutical environments.

The system’s dual support for single-use and reusable configurations is particularly relevant as biopharma facilities shift toward hybrid plants that use disposable technologies where they add flexibility but retain stainless-steel in specific unit operations. Sartorius positions Sartoflow Advance as a way for customers to run high-value clinical batches and even selected commercial products on single-use flow kits while still having the option to operate in more traditional modes when appropriate. This flexibility can reduce cleaning validation efforts, shorten downtimes between campaigns and support multi-product facilities where rapid sequence changes are the norm, especially in contract manufacturing settings. At the same time, having a common skid platform for both configurations helps standardize operator training and maintenance routines, which can reduce complexity and error risk in plants that already run multiple process variants. For investors and industry observers, the product underscores how mid-scale TFF equipment is evolving to serve both established blockbuster biologics and increasingly diversified pipelines that include smaller, targeted therapies.

Market analysts tracking tangential flow filtration have highlighted robust growth expectations for these systems over the coming decade as global biologics capacity expands and more facilities adopt single-use or hybrid purification steps. One recent industry outlook projects that the global market for tangential flow filtration units could grow at a high single-digit to low double-digit compound annual rate through the mid-2030s, driven by new monoclonal antibody plants, vaccine manufacturing capacity and non-biopharma applications that also rely on high-performance filtration. A forecast from IndexBox points to an 8 to 12 percent annual growth range for tangential flow filtration units through 2035, underscoring why suppliers like Sartorius are refining their offerings for scalable, standardized platforms. Against this backdrop, Sartoflow Advance is aimed squarely at biopharma companies and contract manufacturers that want to expand capacity fast without locking themselves into only stainless-steel or only single-use hardware, reflecting a broader industry preference for modular and flexible systems. The focus on mid-scale working volumes also aligns with the growing importance of clinical and niche commercial products, where batch sizes are smaller but regulatory and quality demands remain high.

Sartoflow Advance is part of Sartorius Stedim’s broader strategy to position itself as a full-line provider of integrated bioprocess solutions spanning cell culture, harvest, clarification, chromatography and final filtration. The company has repeatedly stressed in its communications that single-use systems and related technologies remain core to its growth agenda, as customers continue to build new facilities around flexible, disposable infrastructure. On the official Sartoflow Advance product page, Sartorius highlights the platform as a scalable, modular TFF system optimized for ultrafiltration and diafiltration steps in modern biologics manufacturing, reinforcing its role within the company’s downstream portfolio. At the same time, Sartorius Stedim regularly updates investors that demand for single-use and filtration technologies is tied closely to the build-out of new biologics plants worldwide, making products like Sartoflow Advance strategically relevant even though pricing is typically handled on a quotation basis rather than via public list prices. Shares of Sartorius Stedim Biotech (FR0013154002) are listed on Euronext Paris; according to recent market data, the stock last traded around EUR 180 on 06/13/2026, reflecting investor attention to bioprocess equipment demand. The company’s investor relations page provides additional background on its filtration and single-use growth strategy.

Sartoflow Advance in brief: the hard facts

• Product: Sartoflow Advance
• Manufacturer: Sartorius Stedim Biotech SA
• Category: New Release - tangential flow filtration system
• Launch date: Recent addition to Sartorius Stedim tangential flow filtration portfolio
• MSRP / Price: Not publicly listed; pricing on request based on configuration
• Availability: Available to biopharma manufacturers and CDMOs via Sartorius sales representatives and online contact channels
• Target audience: Biopharmaceutical manufacturers and contract development and manufacturing organizations requiring flexible mid-scale UF/DF capability
• Key differentiator / USP: Modular TFF skid that supports both single-use and reusable configurations for concentration and diafiltration of biologics at working volumes from a few liters up to around 200 liters

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.